Camzyos Patent Expiration

Camzyos is a drug owned by Bristol Myers Squibb Co. It is protected by 2 US drug patents filed in 2022 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 19, 2034. Details of Camzyos's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9181200 Pyrimidinedione compounds
Jun, 2034

(9 years from now)

Active
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 Pyrimidinedione compounds
Jun, 2034

(9 years from now)

Active


FDA has granted several exclusivities to Camzyos. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Camzyos, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Camzyos.

Exclusivity Information

Camzyos holds 3 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2029. Details of Camzyos's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
M(M-297) Jun 15, 2026
New Chemical Entity Exclusivity(NCE) Apr 28, 2027
Orphan Drug Exclusivity(ODE-398) Apr 28, 2029

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Camzyos is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Camzyos's family patents as well as insights into ongoing legal events on those patents.

Camzyos's family patents

Camzyos has patent protection in a total of 34 countries. It's US patent count contributes only to 20.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Camzyos.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Camzyos's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jun 19, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Camzyos Generics:

There are no approved generic versions for Camzyos as of now.





About Camzyos

Camzyos is a drug owned by Bristol Myers Squibb Co. It is used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III. Camzyos uses Mavacamten as an active ingredient. Camzyos was launched by Bristol in 2022.

Market Authorisation Date:

Camzyos was approved by FDA for market use on 28 April, 2022.

NCE-1 date:

NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Camzyos is 28 April, 2022, its NCE-1 date is estimated to be 28 April, 2026

Active Ingredient:

Camzyos uses Mavacamten as the active ingredient. Check out other Drugs and Companies using Mavacamten ingredient

Treatment:

Camzyos is used for improving functional capacity and symptoms in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in NYHA class II-III.

Dosage:

Camzyos is available in capsule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
2.5MG CAPSULE Prescription ORAL
5MG CAPSULE Prescription ORAL
10MG CAPSULE Prescription ORAL
15MG CAPSULE Prescription ORAL